414 related articles for article (PubMed ID: 30041785)
1. Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors.
Breuker C; Clement F; Mura T; Macioce V; Castet-Nicolas A; Audurier Y; Boegner C; Morcrette E; Jalabert A; Villiet M; Avignon A; Sultan A
Int J Cardiol; 2018 Oct; 268():195-199. PubMed ID: 30041785
[TBL] [Abstract][Full Text] [Related]
2. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
[TBL] [Abstract][Full Text] [Related]
3. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients.
Xanthopoulou I; Davlouros P; Siahos S; Perperis A; Zaharioglou E; Alexopoulos D
Lipids Health Dis; 2013 Nov; 12():170. PubMed ID: 24209409
[TBL] [Abstract][Full Text] [Related]
5. Statin Therapy in Patients With Low Serum Levels of Low-Density Lipoprotein Cholesterol.
Tsujimoto T; Kajio H; Sugiyama T
Am J Cardiol; 2017 Dec; 120(11):1947-1954. PubMed ID: 28951019
[TBL] [Abstract][Full Text] [Related]
6. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
7. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan.
Teramoto T; Uno K; Miyoshi I; Khan I; Gorcyca K; Sanchez RJ; Yoshida S; Mawatari K; Masaki T; Arai H; Yamashita S
Atherosclerosis; 2016 Aug; 251():248-254. PubMed ID: 27419905
[TBL] [Abstract][Full Text] [Related]
9. Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).
Boytsov S; Logunova N; Khomitskaya Y;
Cardiovasc Diabetol; 2017 Dec; 16(1):158. PubMed ID: 29246151
[TBL] [Abstract][Full Text] [Related]
10. [Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
Degli Esposti L; Sangiorgi D; Arca M; Vigna GB; Budal S; Degli Esposti E
Monaldi Arch Chest Dis; 2011 Dec; 76(4):160-7. PubMed ID: 22567731
[TBL] [Abstract][Full Text] [Related]
11. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
12. Frequency and predictors of cholesterol target attainment in patients with stable coronary heart disease in Belgium: results from the Dyslipidemia International Study II (DYSIS II
Hermans MP; Gevaert S; Descamps O; Missault L; Gillot B; De Keyzer D; Lautsch D; Brudi P; Ambegaonkar B; Vyas A; Horack M; Gitt A
Acta Clin Belg; 2019 Dec; 74(6):399-404. PubMed ID: 30355016
[No Abstract] [Full Text] [Related]
13. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
[TBL] [Abstract][Full Text] [Related]
14. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
[TBL] [Abstract][Full Text] [Related]
15. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
16. Situational Analysis of Low-density Lipoprotein Cholesterol Control and the Use of Statin Therapy in Diabetes Patients Treated in Community Hospitals in Nanjing, China.
Ouyang XJ; Zhang YQ; Chen JH; Li T; Lu TT; Bian RW
Chin Med J (Engl); 2018 Feb; 131(3):295-300. PubMed ID: 29363644
[TBL] [Abstract][Full Text] [Related]
17. Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical records.
García-Gil M; Blanch J; Comas-Cufí M; Daunis-i-Estadella J; Bolíbar B; Martí R; Ponjoan A; Alves-Cabratosa L; Ramos R
J Clin Lipidol; 2016; 10(1):134-42. PubMed ID: 26892130
[TBL] [Abstract][Full Text] [Related]
18. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
[TBL] [Abstract][Full Text] [Related]
19. [Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].
Li Y; Zhao SP; Ye P; Yan XW; Mu YM; Wei YD; Hu DY;
Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Aug; 44(8):665-70. PubMed ID: 27545124
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.
Wong ND; Young D; Zhao Y; Nguyen H; Caballes J; Khan I; Sanchez RJ
J Clin Lipidol; 2016; 10(5):1109-18. PubMed ID: 27678427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
